Blend CJC 1295 NO DAC 5mg with GHRP-2 5mg

This blend pairs CJC-1295 NO-DAC, a 29-residue GHRH analog, with GHRP-2, a hexapeptide secretagogue distinguished from related peptides in its class by a D-2-naphthylalanine substitution at the position occupied by D-tryptophan in the earlier GHRP-6 scaffold.

GHRP-2 Structural Considerations

GHRP-2's bulkier naphthyl side chain is thought to improve hydrophobic contact within the growth hormone secretagogue receptor's binding pocket relative to earlier secretagogues in this peptide family, a structural distinction frequently referenced in laboratory literature on GHRP-class binding characteristics.

CJC-1295 NO-DAC Receptor Engagement Research

Structural and computational research has examined the dynamic properties of the GHRH receptor and the molecular determinants of GHRH binding, providing a receptor-level basis for how CJC-1295 NO-DAC's GHRH-derived sequence is understood to engage this receptor.¹

CJC-1295 NO-DAC Peptide Design

Native GHRH is rapidly degraded in plasma through cleavage by dipeptidyl peptidase-IV near the N-terminus, along with chemical rearrangement and oxidation elsewhere in the sequence.

These degradation pathways are the chemical basis for the four stabilizing substitutions built into CJC-1295 NO-DAC, which are designed to resist these specific routes of enzymatic and chemical inactivation and give the peptide improved stability relative to unmodified GRF(1-29) in laboratory research.

Combined Research Applications

Because CJC-1295 NO-DAC and GHRP-2 engage separate receptor pathways, GHRH receptor and growth hormone secretagogue receptor respectively, this blend is studied for research into potential convergence between the two signaling pathways within a single experimental platform.

The specific consequences of pairing GHRH-receptor and growth hormone secretagogue receptor signaling in a single formulation remain an open question in laboratory research, with available data on such combinations still preliminary.

Analytical Verification for Blended Products

The nearly five-fold size difference between CJC-1295 NO-DAC and GHRP-2 means a single aggregate purity figure cannot confirm that both components are present in their correct proportion.

Researchers reviewing documentation for this blend are encouraged to look for individual HPLC or mass spectrometry data for CJC-1295 NO-DAC and GHRP-2 separately, with attention to potential byproducts arising during coupling of GHRP-2's bulky D-2-Nal residue.

Storage and Handling in the Laboratory Setting

The lyophilized blend is stored under sub-zero freezer conditions, with the powder kept away from prolonged light exposure, reflecting the more conservative handling requirement between CJC-1295 NO-DAC's longer chain length and GHRP-2's aromatic residue content.

Important Notice

CJC-1295 NO-DAC with GHRP-2 is intended strictly for in vitro laboratory research only and is not for human consumption, diagnostic use, or therapeutic use. Researchers utilize this product to investigate growth hormone-related receptor signaling mechanisms under controlled experimental conditions, and it has not been evaluated for safety or efficacy in humans.

Product Information

CJC-1295 NO-DAC with GHRP-2 is supplied as a white lyophilized powder at a concentration of 10 mg per vial (5 mg of each peptide).

References

1. Matsoukas MT, Spyroulias GA. Dynamic properties of the growth hormone-releasing hormone receptor (GHRHR) and molecular determinants of GHRH binding. Mol Biosyst. 2017;13(7):1313-1322.